The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation’s top cancer centers calling for increased human papillomavirus (HPV) vaccination for the prevention of cancer.
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
A new targeted therapy for hard-to-treat chronic lymphocytic leukemia appears to have fewer side effects than a previous therapy.
Columbia researchers Andrea Califano and Jean Gautier have received prestigious NCI awards that support and encourage leaders in cancer research.
Columbia has one of six new sites launched by the NIH's Breast Cancer and Environment Research Program for prevention and research across the lifespan.